ClinicalTrials.gg
RecruitingNCT07391579Updated Feb 6, 2026

Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients

A Phase 4 interventional study of Tadalafil 5 mg & Sildenafil 100mg and Sildenafil 100mg & placebo in Erectile Dysfunctions, sponsored by Mansoura University. Recruiting at 11 sites in Egypt. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Mansoura University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
21 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Planned enrollment
11th of 56
500 · median 199
Started
2025
with 6 others
Phase 4
26 of 57
3 open now
Registered
49th of 57
by date

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 11th largest by planned enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2025, is one of 26 in phase 4, and was the 49th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 21 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether daily dosing with tadalafil 5 mg combined with on-demand sildenafil 100 mg can improve erectile function in men with erectile dysfunction (ED) who do not respond to PDE5 inhibitor alone.

The main questions it aims to answer are:

  • Does the combination of daily tadalafil and on-demand sildenafil lead to a greater improvement in erectile function (measured by the IIEF-EF domain) compared with on-demand sildenafil alone?
  • Is the combination therapy safe and well tolerated in this patient population?

Researchers will compare:

  • Group A: Daily tadalafil 5 mg plus on-demand sildenafil 100 mg
  • Group B: Daily placebo plus on-demand sildenafil 100 mg

to determine whether the combination regimen provides superior improvement in erectile function and patient satisfaction.

Participants will:

  • Undergo baseline assessment including medical history, physical examination, and laboratory tests.
  • Be randomly assigned to one of the two treatment groups.
  • Take the assigned medications for 12 weeks.
  • Complete follow-up evaluations at 4, 8, and 12 weeks, including:

International Index of Erectile Function (IIEF-15) questionnaire Erection Hardness Score (EHS) assessment Reporting of any adverse effects

03

Conditions studied

  • Erectile Dysfunctions

Browse trials for

Keywords

  • Erectile Dysfunction
  • ED
  • Sildenafil
  • Tadalafil
  • PDE5i Non-Responders
  • Combination Therapy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sexually active male.
  • History of ED for ≥6 months.
  • Erectile function domain of IIEF-15 score \<17.
  • Documented failure to respond to PDE-5I [definition of non-responder patients are patients with ED who don't respond to maximum dose of PDE-5I on ≥4 occasions in spite of accurate timing and good sexual stimulation].
  • Stable sexual relationship ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • Penile anatomical deformities or Peyronie's disease.
  • Pelvic surgery or radiation.
  • Active or severe systemic illness.
  • Previous penile surgery of any kind, such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication or grafting.
  • to PDE5i (High risk cardiac patients, patients on nitrates, hypotension).
  • Using other treatments for ED e.g., Intra-cavernoasl prostaglandin injection therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Group A

    Daily tadalafil 5 mg and on-demand sildenafil 100 mg

    Drug: Tadalafil 5 mg & Sildenafil 100mg

  • Placebo comparator
    Group B

    daily Placebo and on demand sildenafil 100 mg

    Drug: Sildenafil 100mg & placebo

Interventions

  • daily dosing of Tadalafil 5 mg combined with on demand Sildenafil 100mg

  • DrugSildenafil 100mg & placebo

    Daily Placebo combined with on demand Sildenafil 100mg

06

What researchers measure

Primary outcomes

  1. Change in International Index of Erectile Function-5 (IIEF-5) total score

    The IIEF-5 is a validated 5-item questionnaire assessing erectile function, with total scores ranging from 5 to 25; higher scores indicate better erectile function.

    Time frame: from baseline to 12 weeks after starting treatment

Secondary outcomes

  1. Change in Erection Hardness Score (EHS), assessed using the validated 4-point Erection Hardness Scale

    The Erection Hardness Score (EHS) is a validated 4-point scale assessing penile rigidity, with higher scores indicating better erectile hardness.

    Time frame: from baseline to 12 weeks after starting treatment

  2. Change in International Index of Erectile Function (IIEF-15) total score

    The International Index of Erectile Function (IIEF-15) is a validated 15-item questionnaire assessing erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction, with total scores ranging from 5 to 75; higher scores indicate better sexual function.

    Time frame: from baseline to 12 weeks after treatment

  3. Incidence and severity of adverse events graded according to CTCAE version 5.0

    Adverse events will be recorded at each follow-up visit and classified by type, severity, and relationship to the intervention. Severity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: from baseline up to 12 weeks after treatment

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 16 phase 4 interventional studies under Erectile Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Feb 6, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07391579
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Dec 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Ahmed A Shokeir+2, professor of Urology
Contact
ahmed.shokeir@hotmail.com
+201121102929
Ahmed A Shokeir, professor of urology
study chair · Urology & Nephrology Center, Masnoura university, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion